Insulin detemir reduces the risk of hypoglycaemia at all levels of HbA1c compared to NPH insulin in the context of basal-bolus therapy for type 1 diabetes

被引：0
|
作者：
Jones, DR
Kim, H
Heller, S
Clauson, P
机构：
[1] Royal Surrey Cty Hosp, Dept Endocrinol & Diabet, Guildford, Surrey, England
[2] Univ Sheffield, Sheffield, S Yorkshire, England
[3] Novo Nordisk AS, DK-2880 Bagsvaerd, Denmark
来源：
DIABETOLOGIA | 2005年 / 48卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
243
引用
收藏
页码：A92 / A93
页数：2
相关论文
共 50 条
  • [31] An economic assessment of analogue basal-bolus insulin versus human basal-bolus insulin in subjects with type 1 diabetes in the UK
    Palmer, Andrew J.
    Valentine, William J.
    Ray, Joshua A.
    Foos, Volker
    Lurati, Francesco
    Smith, Inger
    Lammert, Morten
    Roze, Stephane
    CURRENT MEDICAL RESEARCH AND OPINION, 2007, 23 (04) : 895 - 901
  • [32] More subjects achieve an HbA1c ≤7% without hypoglycaemia or weight gain when treated with insulin detemir in comparison with NPH insulin
    Hermansen, K.
    Larsen, J.
    Tamer, S. C.
    Mathieu, C.
    DIABETOLOGIA, 2007, 50 : S412 - S412
  • [33] Cost-effectiveness of detemir based basal-bolus therapy versus NPH for type 1 diabetes in a Spanish setting
    Ray, J. A.
    Valentine, W. J.
    Goodall, G.
    Aagren, M.
    Kotchie, R. W.
    DIABETOLOGIA, 2007, 50 : S428 - S428
  • [34] Is hypoglycaemia an increasing barrier to achieving HbA1c target for NPH insulin than insulin glargine?
    Zhang, Q.
    Chou, E.
    Chung, H-W.
    Wang, H.
    DIABETOLOGIA, 2014, 57 : S262 - S263
  • [35] Basal-bolus therapy with insulin detemir/insulin aspart improves glycaemic control and reduces hypoglycaemia: data from the German cohort of the PREDICTIVE study
    Ackermann, R. W.
    Hansen, J. B.
    Nauck, M.
    DIABETOLOGIA, 2006, 49 : 595 - 596
  • [36] More subjects treated with insulin detemir achieve HbA1c ≤ 7% without hypoglycemia and weight gain compared to NPH insulin
    Hermansen, Kjeld
    Larsen, Jens
    Tamer, Soren C.
    Mathieu, Chantal
    DIABETES, 2007, 56 : A130 - A130
  • [37] OPTIMAL REGIMENS OF THE BASAL-BOLUS INSULIN THERAPY IN ADOLESCENTS WITH TYPE 1 DIABETES MELLITUS
    Galkina, G. A.
    Voropay, A. A.
    Levkovich, M. A.
    Vorobiov, S. V.
    Komkova, M. V.
    Morozova, N. V.
    BYULLETEN SIBIRSKOY MEDITSINY, 2015, 14 (05): : 15 - U223
  • [38] Metabolic control by insulin detemir in basal-bolus therapy: treat-to-target study in children and adolescents with type 1 diabetes
    Nimri, Revital
    Lebenthal, Yael
    Shalitin, Shlomit
    Benzaquen, Hadasa
    Demol, Sharon
    Phillip, Moshe
    PEDIATRIC DIABETES, 2013, 14 (03) : 196 - 202
  • [39] A randomized trial comparing the efficacy and safety of treating patients with type 2 diabetes and highly elevated HbA1c levels with basal-bolus insulin or a glucagon-like peptide-1 receptor agonist plus basal-bolus insulin: The SIMPLE study
    Abreu, Marconi
    Tumyan, Anna
    Elhassan, Ahmed
    Peicher, Katherine
    Papacostea, Olivia
    Dimachkie, Perihan
    Siddiqui, Muhammad S.
    Pop, Laurentiu M.
    Gunasekaran, Uma
    Meneghini, Luigi F.
    Adams-Huet, Beverley
    Li, Xilong
    Lingvay, Ildiko
    DIABETES OBESITY & METABOLISM, 2019, 21 (09): : 2133 - 2141
  • [40] A comparison of the cost-effectiveness for basal-bolus therapy of type 1 diabetes using insulin detemir plus insulin aspart or human insulin-based regimens
    Palmer, AJ
    Roze, S
    Valentine, WJ
    Schmidt, I
    Wittrup-Jensen, KW
    DIABETES, 2004, 53 : A288 - A288
12345